Search results
Results from the WOW.Com Content Network
TAP Pharmaceuticals was formed in 1977 as a joint venture between the two global pharmaceutical companies, Abbott Laboratories and Takeda Pharmaceutical Co. and was dissolved in 2008; its two most lucrative products were proton-pump inhibitor lansoprazole (Prevacid) and the prostate cancer drug, leuprorelin (Lupron). [1]
In 2001, TAP's illegal marketing of Lupron resulted in both civil and criminal charges by the U.S. Department of Justice and the Illinois attorney general for federal and state medicare fraud. TAP was fined $875 million, then reported as the largest pharmaceutical settlement in history. [48] [49] In March 2008, Takeda and Abbott Laboratories ...
The following is a list of the 21 largest civil settlements, reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2017, ordered by the size of the total civil settlement. Some of these matters also resolved criminal fines and penalties, listed in parentheses, but these amounts are not considered when ...
In October 2001, the US Department of Justice, states attorneys general, and TAP Pharmaceutical Products, a subsidiary of Abbott Laboratories, settled criminal and civil charges against TAP related to federal and state medicare fraud and illegal marketing of the drug leuprorelin. [53]
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
Feminine products. PPE. Pregnancy tests. Reading glasses. This list is not exhaustive. Employees should consult the terms of their HRA for more information about eligible expenses.
The varieties of dairy products available abroad are often more easy to tolerate for lactose-intolerant folks, too. Dietitian Amy Goldsmith, RDN, LDN, ...
Asoprisnil (INN; developmental code name J-867) is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids. [1] In 2005, phase III clinical trials were discontinued due to endometrial changes in patients. [2]